Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
The company was incorporated in 1990 and is headquartered in Foster City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -0.04 Increased by +50.00% | -0.08 Increased by +50.00% |
| Aug 8, 24 | -0.10 Decreased by -11.11% | -0.10 |
| May 2, 24 | -0.09 Decreased by -28.57% | -0.10 Increased by +10.00% |
| Feb 28, 24 | -0.09 Increased by +10.00% | -0.10 Increased by +10.00% |
| Nov 2, 23 | -0.08 Increased by +20.00% | -0.10 Increased by +20.00% |
| Aug 3, 23 | -0.09 Decreased by -28.57% | -0.08 Decreased by -12.50% |
| May 11, 23 | -0.07 Increased by +22.22% | -0.10 Increased by +30.00% |
| Mar 16, 23 | -0.10 Increased by 0.00% | -0.12 Increased by +16.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 28.27 M Increased by +17.14 K% | -26.45 M Increased by +40.97% | Decreased by -93.55% Increased by +99.66% |
| Jun 30, 24 | 882.00 K Increased by +2.94 K% | -67.38 M Decreased by -36.88% | Decreased by -7.64 K% Increased by +95.50% |
| Mar 31, 24 | 304.00 K Increased by +1.35 K% | -55.39 M Decreased by -45.48% | Decreased by -18.22 K% Increased by +89.95% |
| Dec 31, 23 | 23.00 K Decreased by -77.67% | -51.97 M Decreased by -22.56% | Decreased by -225.97 K% Decreased by -448.87% |
| Sep 30, 23 | 164.00 K Decreased by -44.78% | -44.80 M Decreased by -9.75% | Decreased by -27.32 K% Decreased by -98.75% |
| Jun 30, 23 | 29.00 K Decreased by -60.27% | -49.23 M Decreased by -74.21% | Decreased by -169.75 K% Decreased by -338.52% |
| Mar 31, 23 | 21.00 K Decreased by -82.93% | -38.07 M Decreased by -20.79% | Decreased by -181.30 K% Decreased by -607.48% |
| Dec 31, 22 | 103.00 K Decreased by -90.10% | -42.41 M Decreased by -32.45% | Decreased by -41.17 K% Decreased by -1.24 K% |